Insulet (NASDAQ:PODD – Get Free Report)‘s stock had its “outperform” rating restated by equities research analysts at Raymond ...
Insulet (NASDAQ:PODD – Get Free Report) had its price objective boosted by analysts at Piper Sandler from $285.00 to $310.00 ...
Insulet Corporation PODD reported fourth-quarter 2024 adjusted earnings per share (EPS) of $1.15, down significantly 17.8% ...
Insulin delivery company Insulet Corporation (NASDAQ:PODD) reported Q4 CY2024 results , with sales up 17.2% year on year to ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Insulet (PODD – Research Report), Prothena (PRTA – Research ...
Insulet's impressive growth with its Omnipod system, robust 2024 results, and surging valuation make it attractive. See more ...
Insulet (PODD) reported $597.5 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 17.2%. EPS of $1.15 for the same period compares to $1.40 a year ago.
Insulet (PODD) delivered earnings and revenue surprises of 9.52% and 2.73%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Insulin delivery company Insulet Corporation (NASDAQ:PODD) will be announcing earnings results tomorrow after market close. Here’s what to expect. Insulet beat analysts’ revenue expectations ...
Insulet (PODD) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.05 per share. This compares to earnings of $1.40 per share a year ago. These figures ...